REGN analyst estimates
Regeneron (REGN) analyst ratings, the average price target and its range, and every firm's latest call.
REGN analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 30, 2026 | Robert W. Baird | Regeneron Pharma (REGN) PT Raised to $875 at Baird | $875.00 |
| Oct 19, 2026 | Piper Sandler | Regeneron price target raised to $865 from $854 at Piper Sandler | $865.00 |
| Oct 14, 2026 | UBS | Regeneron assumed with Buy from Neutral at UBS | $978.00 |
| Oct 8, 2026 | Raymond James | Raymond James maintains Outperform rating on Regeneron with $911 target | $911.00 |
| Oct 8, 2026 | RBC Capital | Regeneron price target raised to $810 from $737 at RBC Capital | $810.00 |
| Oct 7, 2026 | Morgan Stanley | Regeneron price target raised to $779 from $758 at Morgan Stanley | $779.00 |
| Oct 7, 2026 | Truist Financial | Regeneron price target raised to $780 from $772 at Truist | $780.00 |
| Oct 1, 2026 | Argus Research | Argus upgrades Regeneron on attractive entry point after selloff | $850.00 |
| Oct 1, 2026 | BMO Capital | BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN) | $920.00 |
| Oct 1, 2026 | Jefferies | Regeneron price target raised to $930 from $870 at Jefferies | $930.00 |
| Sep 10, 2026 | HSBC | Regeneron price target raised to $920 from $800 at HSBC | $920.00 |
| Aug 17, 2026 | Leerink Partners | Regeneron price target raised to $824 from $641 at Leerink | $824.00 |
| Aug 14, 2026 | Bernstein | Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group | $756.00 |
| Aug 3, 2026 | Guggenheim | Regeneron price target raised to $1,030 from $1,000 at Guggenheim | $1,030.00 |
| Jul 31, 2026 | RBC Capital | Regeneron price target raised to $737 from $696 at RBC Capital | $737.00 |
- 25 firms rate REGN: 17 buy, 8 hold, 0 sell.
- The average price target is $873.43 from 14 analysts, from $756.00 to $1,030.00.
Updated 2026-11-07 11:54 UTC